Development of novel prodrugs targeting glutamate dehydrogenase (GDH) for the treatment of congenital hyperinsulinemia disorder including hyperinsulinemia-hyperammonemia syndrome (HHS) and schad-HI.
Ended Project Grant Awarded Last action
- Award ID
- R43DK115229
- Recipient
-
Avanti Biosciences, Inc. UEI GZNJSM9ELXB3
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $298,999
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- Stony Brook, NY 11790, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $12,000 | $0 | |
| Amendment | $12,000 | $12,000 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | -$12,000 | $0 | |
| Amendment | -$12,000 | -$12,000 | |
| Amendment | $0 | $0 | |
| Original award | $298,999 | $0 |
Quick answers
Who received award R43DK115229?
R43DK115229 was awarded to Avanti Biosciences, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on August 1, 2018.
How much is award R43DK115229 worth?
$298,999 has been obligated on R43DK115229.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award